• 研究課題をさがす
  • 研究者をさがす
  • KAKENの使い方
  1. 前のページに戻る

Development of a novel multifunctional nanoliposome-based system for maintaining active agent concentration in tumor tissue during boron-neutron capture therapy

研究課題

研究課題/領域番号 23K06738
研究種目

基盤研究(C)

配分区分基金
応募区分一般
審査区分 小区分50020:腫瘍診断および治療学関連
研究機関筑波大学

研究代表者

ザボロノク アレクサンドル  筑波大学, 医学医療系, 助教 (20723117)

研究分担者 石川 栄一  筑波大学, 医学医療系, 教授 (30510169)
白川 真  福山大学, 薬学部, 講師 (40707759)
中井 啓  筑波大学, 医学医療系, 准教授 (50436284)
鶴淵 隆夫  筑波大学, 医学医療系, 講師 (70778901)
MATHIS BRYAN  筑波大学, 医学医療系, 准教授 (80794635)
研究期間 (年度) 2023-04-01 – 2026-03-31
研究課題ステータス 交付 (2023年度)
配分額 *注記
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2025年度: 1,820千円 (直接経費: 1,400千円、間接経費: 420千円)
2024年度: 1,560千円 (直接経費: 1,200千円、間接経費: 360千円)
2023年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
キーワードliposomes / glioma / BNCT / carboranes / nanoparticles / boron / gold / active tumor targeting / tumor targeting
研究開始時の研究の概要

Synthesis and application of liposome-based theranostic nanoparticle complex superior to existing compounds for boron neutron capture therapy (BNCT) implemented by our research group will solve the problem of large boron amount delivery and its retention in tumor cells during neutron irradiation needed for successful neutron capture reaction and dosimetry in cancer treatment using BNCT.

研究実績の概要

In the 2023 fiscal year, we completed the synthesis of liposomes as planned, setting the stage for the integration of the active tumor targeting component, which is scheduled for the final stage before animal experiments. Gold nanoparticles were employed at varying concentrations to create complex liposomes. We examined the composition using transmission electron microscopy (TEM), which helped us determine the optimal amount of gold necessary for effective targeting linkage and visualization. All necessary components have been prepared or synthesized for additional modifications of the liposomes and the inclusion of boron compounds in both the water phase and the bilipid layer. Several boron compounds/nanoparticles were evaluated as potential integrants for the liposomes. Notably, three types of carboranes and boron-containing magnetic nanoparticles demonstrated adequate cellular tolerability and effective boron accumulation in tumor cells. Initially, human T98 glioma cells were used in these experiments. The liposomes remained stable in aqueous solutions for weeks to months, allowing for ongoing TEM analysis during their storage. Additional experiments were conducted to examine irradiation settings at the accelerator, using large animals and a low-molecular-weight boron compound. Various aspects of these irradiation experiments were analyzed to inform future implementations with liposomes. Although the study was delayed due to one of the researchers transferring to another university, it will continue as planned, as he will still participate in the study.

現在までの達成度 (区分)
現在までの達成度 (区分)

3: やや遅れている

理由

The study was delayed because one of the researchers transferred to another university. For liposome synthesis, some additional equipment was needed, which was purchased at the new location. However, this acquisition took some time. Despite these delays, the study will continue as planned.

今後の研究の推進方策

In the next fiscal year, we aim to advance our work by refining the synthesis of complex liposomes, incorporating gold nanoparticles for both diagnostic purposes and linkage to the targeting system. Our research will extend to developing an experimental animal tumor model tailored for liposome application and conducting in vitro evaluations to assess delivery mechanisms, using the same cell lines planned for the animal studies. Additionally, we will focus on the accumulation of core compounds, dosimetry, and analyzing the tumor cell-killing effects of neutrons irradiated from an accelerator or nuclear reactor on cells with accumulated complex liposomes. We will also select the most suitable cell lines for these experiments and initiate animal studies to evaluate nanoliposome toxicity.

報告書

(1件)
  • 2023 実施状況報告書
  • 研究成果

    (1件)

すべて 2023

すべて 学会発表 (1件)

  • [学会発表] 新規 BNCT 用薬剤としてのイオン液 体の評価2023

    • 著者名/発表者名
      1.白川 真、河本 紗季、Alexander Zaboronok, 熊田 博明”、榮 武二、松村 明、亀川 展幸、竹内 亮太、堀 均、鈴木 実
    • 学会等名
      第19回日本中性子捕捉療法学会, Yokohama, Japan, 2023.07.13-15.
    • 関連する報告書
      2023 実施状況報告書

URL: 

公開日: 2023-04-13   更新日: 2024-12-25  

サービス概要 検索マニュアル よくある質問 お知らせ 利用規程 科研費による研究の帰属

Powered by NII kakenhi